IMR Press / CEOG / Volume 28 / Issue 4 / pii/2001059

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report

A case report demonstrating that follicle maturing drugs may create an adverse uterine environment even when not used for controlled ovarian hyperstimulation

Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2001, 28(4), 217–218;
Published: 10 December 2001

Purpose: To evaluate whether follicle maturing drugs used in lower dosages for luteal phase defects rather than controlled ovarian hyperstimulation may have an adverse effect on successful implantation. Methods: Unique case report. Results: A 40-year-old woman who failed to conceive after six years of follicle maturing drugs with or without progesterone sup­plementation and four years of in vitro fertilization with embryo transfer (92 embryos transferred in 10 cycles) successfully con­ceived with the first cycle after the exclusive use of vaginal progesterone in the luteal phase. Conclusions: This case provides convincing evidence that for some women follicle maturing drugs, even when used in lower dosages, can adversely affect the uterine environment.

Follicle maturing drugs
Adverse uterine environment
Refractory infertility
Progesterone supplementation
Back to top